MGTA Magenta Therapeutics Inc.

13.53
0  0%
Previous Close 13.53
Open
Price To Book 3.27
Market Cap 527,528,165
Shares 38,989,517
Volume 0
Short Ratio
Av. Daily Volume 159,057
Stock charts supplied by TradingView

NewsSee all news

  1. Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals

    New MGTA-117 ADC clinical candidate for conditioning demonstrates broad therapeutic index; advancing MGTA-117 to generate initial patient clinical data in 2021 MGTA-145 first-line stem cell mobilization agent on

  2. Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to

  3. Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its CD117-ADC

  4. First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its MGTA-145 stem

  5. Magenta Therapeutics to Present at the Evercore ISI HealthCONx Conference on Tuesday, December 3rd

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Will evaluate development as less toxic conditioning becomes available.
MGTA-456
Sickle cell disease
Phase 2 data noted all patients met primary endpoint.
MGTA-456
Inherited Metabolic Disorders (IMD)
Phase 2 data presented at ASH December 9, 2019.
MGTA-456
Acute Lymphoblastic Leukemia
Phase 1 initial data at ASH December 7, 2019 - safe and well-tolerated.
MGTA-145
Healthy volunteers
Phase 1 trial to be initiated 2020 with data due 2021.
MGTA-117

Latest News

  1. Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals

    New MGTA-117 ADC clinical candidate for conditioning demonstrates broad therapeutic index; advancing MGTA-117 to generate initial patient clinical data in 2021 MGTA-145 first-line stem cell mobilization agent on

  2. Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to

  3. Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its CD117-ADC

  4. First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its MGTA-145 stem

  5. Magenta Therapeutics to Present at the Evercore ISI HealthCONx Conference on Tuesday, December 3rd

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled

  6. Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    –Early clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of cells in 11 of 12 healthy volunteers; updated data to be presented at ASH–  –Reported first-ever successful gene

  7. Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR

    -- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis -- -- Magenta exercises option with Heidelberg Pharma

  8. Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting

    -- First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in 11 of 12 healthy volunteers within hours; updated data including apheresis collection to be presented

  9. Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the U.S. Food and Drug